PMEF
HRTX icon

Point72 Middle East FZE’s Heron Therapeutics HRTX Stock Holding History

Point72 Middle East FZE’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,500
Closed -$31.4K – 616
2023
Q4 		$31.4K Buy
+18,500
New +$20.4K ﹤0.01% 1329
2023
Q3 		– Sell
-67,821
Closed -$78.7K – 1630
2023
Q2 		$78.7K Buy
+67,821
New +$121K ﹤0.01% 1238
2023
Q1 		– Sell
-14,878
Closed -$37.2K – 1876
2022
Q4 		$37.2K Buy
+14,878
New +$47.9K ﹤0.01% 1521

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Middle East FZE's HRTX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Heron Therapeutics (HRTX) in Q1 2024, closing a stake of 18,500 shares — an estimated $31.4K sold.

Point72 Middle East FZE first reported a position in HRTX in Q4 2022 and held it in 3 quarters. The position peaked at $78.7K in Q2 2023. 161 funds tracked by Wall St. Rank hold HRTX as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Heron Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 18,500 Heron Therapeutics shares in Q1 2024, an estimated $31.4K.
  • Point72 Middle East FZE first reported a position in Heron Therapeutics in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Heron Therapeutics position peaked at $78.7K in Q2 2023.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.